Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Queensland Health

Generated: April 23, 2018

DrugPatentWatch Database Preview

Claims for Patent: 4,526,892

« Back to Dashboard

Summary for Patent: 4,526,892
Title: Dimethylaminoalkyl-3-(ergoline-8'.beta.carbonyl)-ureas
Abstract:Novel ergoline derivatives formed by reaction of an 8-carboxy ergoline with a carbodiimide and having hypotensive and antiprolatinic activity.
Inventor(s): Salvati; Patricia (Milan, IT), Caravaggi; Anna M. (Milan, IT), Temperilli; Aldemio (Milan, IT), Bosisio; Germano (Milan, IT), Sapini; Osvaldo (Gallarate, IT), di Salle; Enrico (Milan, IT)
Assignee: Farmitalia Carlo Erba, S.p.A. (Milan, IT)
Application Number:06/448,364
Patent Claims: 1. Compounds of formula ##STR3## wherein R.sub.1 is a hydrogen atom or a methyl group; R.sub.2 is a hydrogen atom; R.sub.3 is a hydrogen atom or a methoxy group; R.sub.4 is an alkyl or an alkenyl group selected from methyl, allyl and propyl groups; and each of R.sub.5 and R.sub.6 independently is an alkyl group having from 1 to 3 carbon atoms or a group of the formula (CH.sub.2).sub.n N(CH.sub.3).sub.2 in which n is 3 with the proviso that at least one of R.sub.5 and R.sub.6 is said dimethylaminoalkyl group, and pharmaceutically acceptable addition salts with organic or inorganic acid thereof.

2. A compound according to claim 1 which is selected from the group consisting of:

1-ethyl-3-(3'-dimethylaminopropyl)-3(6'-methylergoline-8'.beta.-carbonyl)-u rea;

1-ethyl-3-(3'-dimethylaminopropyl)-3-(10'.alpha.-methoxy-6'-methylergoline- 8'.beta.-carbonyl)-urea;

1-(3'-dimethylaminopropyl)-3-ethyl-3-(6'-allylergoline-8'.beta.-carbonyl)-u rea; and

1-ethyl-3-(3'-dimethylaminopropyl)-3-(6'-n-propylergoline-8'.beta.-carbonyl )-urea.

3. A pharmaceutical composition containing a therapeutically effective amount of a compound according to claim 1, in admixture with a pharmaceutically acceptable carrier for oral or parenteral administration.

4. 1-ethyl-3-(3'dimethylaminopropyl)-3-(6'-allylergoline-8'.beta.-carbonyl) -urea.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.